精彩内容12月31日,江苏联环药业提交了依达拉奉右莰醇注射用浓溶液的4类仿制上市申请获得CDE承办。该产品是先声药业于2020年获批的1类新药,2024年在中国三大终端六大市场的销售额超过21亿元。目前,该产品已吸引到10家国内药企申报仿制,首仿之争十分激烈。图1:最新申报的产品情况来源:CDE官网图2:先声药业的依达拉奉右莰醇注射用浓溶液获批情况来源:米内网中国申报进度(MED)数据库先声药业的...
Source Link精彩内容12月31日,江苏联环药业提交了依达拉奉右莰醇注射用浓溶液的4类仿制上市申请获得CDE承办。该产品是先声药业于2020年获批的1类新药,2024年在中国三大终端六大市场的销售额超过21亿元。目前,该产品已吸引到10家国内药企申报仿制,首仿之争十分激烈。图1:最新申报的产品情况来源:CDE官网图2:先声药业的依达拉奉右莰醇注射用浓溶液获批情况来源:米内网中国申报进度(MED)数据库先声药业的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.